Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
文献类型：期刊论文
| 作者 | Zeng, J.2,4; Cui, X.1,3,4; Cheng, L.1,4; Chen, Y.1,4; Du, X.1,4; Sheng, L.1,4 |
| 刊名 | CANCER RADIOTHERAPIE
 |
| 出版日期 | 2021-07-01 |
| 卷号 | 25 |
| 关键词 | Esophageal squamous cell carcinoma Liposome-paclitaxel Chemoradiotherapy Toxicities |
| ISSN号 | 1278-3218 |
| DOI | 10.1016/j.canrad.2021.01.008 |
| 通讯作者 | Sheng, L.(m05shengliming@zju.edu.cn) |
| 英文摘要 | Purpose. - The aim of this study was to evaluate the efficacy of liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Patients and methods. - Seventy-nine consecutive patients treated with liposome-paclitaxel based concurrent chemoradiotherapy between January 2015 and December 2019 at Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang cancer hospital) were enrolled in this study. The overall response, toxicities, progression-free survival and overall survival were analyzed with SPSS software. Results. - A total of 302 cycles of weekly chemotherapy were delivered, with a median 4 courses. After concurrent chemoradiotherapy (CCRT), the efficacy was classified as CR in 4 cases (5.1%), PR in 22 cases (28.2%) and SD in 51 cases (65.4%). The median PFS and OS time were 18.2 months and 23.4 months. The 3-year PFS and OS rates were 45.1% and 43.6%, respectively. Conclusions. - Liposome-paclitaxel and carboplatin concurrent with radiotherapy is a safe and effective modality for locally advanced ESCC. Further clinical investigation are warranted to evaluate the efficacy of this regimen. (C) 2021 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved. |
| WOS关键词 | NEOADJUVANT CHEMORADIOTHERAPY ; RANDOMIZED-TRIAL ; PHASE-II ; CISPLATIN ; CANCER ; CHEMORADIATION ; FLUOROURACIL ; RADIOTHERAPY ; REGIMENS ; TAXANE |
| 资助项目 | Nature Science Foundation of Zhejiang province |
| WOS研究方向 | Oncology ; Radiology, Nuclear Medicine & Medical Imaging |
| 语种 | 英语 |
| WOS记录号 | WOS:000672160500005 |
| 出版者 | ELSEVIER |
| 资助机构 | Nature Science Foundation of Zhejiang province |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/123517]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Sheng, L. |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Radiotherapy, 1 Banshandong Rd, Hangzhou 310022, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg, Hangzhou, Zhejiang, Peoples R China 3.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China 4.Key Lab Diag & Treatment Technol Thorac Oncol, Hangzhou, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zeng, J.,Cui, X.,Cheng, L.,et al. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma[J]. CANCER RADIOTHERAPIE,2021,25. |
| APA | Zeng, J.,Cui, X.,Cheng, L.,Chen, Y.,Du, X.,&Sheng, L..(2021).Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.CANCER RADIOTHERAPIE,25. |
| MLA | Zeng, J.,et al."Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma".CANCER RADIOTHERAPIE 25(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。